Posted on 1/30/17
Better Buy: Johnson & Johnson vs. AbbVie
One company has been in business for 130 years. The other got its start as a stand-alone entity in 2013. But both Johnson & Johnson (NYSE:JNJ) . . .
Posted on 1/30/17
3 Reasons to Buy Pfizer Stock and Never Sell
Buy and hold really hasn't been great advice in the past when it comes to owning Pfizer(NYSE:PFE) stock. Although the big drugmaker's stock has posted decent . . .
Posted on 1/30/17
Johnson & Johnson May Never Recoup Its Costs to Buy Actelion
IMAGE SOURCE: GETTY IMAGES.Healthcare conglomerate Johnson & Johnson (NYSE:JNJ) is arguably one of the most revered, and steadiest, of publicly traded companies in the United States. . . .
Posted on 1/30/17
The Valley Hospital Unveils Plan to Relocate and Build New Hospital
The Valley Hospital will build a new, state-of-the-art hospital in Paramus, announced Audrey Meyers, President and CEO of The Valley Hospital and Valley Health System. Meyers, . . .
Posted on 1/30/17
The Endoscopy Center at St. Mary Partners with Physicians Endoscopy
Physicians Endoscopy, LLC (PE), along with the physicians of the Gastroenterology Group PA, the Center for Colon and Rectal Health, Inc., and St. Mary Medical Center . . .
Posted on 1/27/17
Is GlaxoSmithKline's Dividend Sustainable?
British drugmaker GlaxoSmithKline plc (NYSE:GSK) is one of the top-yielding dividend stocks in the medical sector. Company management has committed to paying a quarterly dividend through . . .
Posted on 1/27/17
Johnson & Johnson's Foolishness Is on Full Display
JOHNSON & JOHNSON CEO ALEX GORSKY. IMAGE SOURCE: JOHNSON & JOHNSON.For quite a number of investors, Johnson & Johnson (NYSE:JNJ) is a staple, long-term holding in . . .
Posted on 1/27/17
Johnson & Johnson's Most Exciting Opportunity
Johnson & Johnson's (NYSE:JNJ) fourth-quarter financials this week suggest that cancer drugs will be the biggest driver of the company's success in 2017. Can cancer drug . . .
Posted on 1/27/17
Celgene's Fastest-Growing Drugs
Celgene Corp (NASDAQ:CELG) is best known for Revlimid, a widely prescribed multiple myeloma therapy that saw sales jump 20% last year to $7 billion. That's impressive . . .
Posted on 1/27/17
Quest Diagnostics Partners With Montefiore Health System
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, is working with Montefiore Health System (MHS) to provide diagnostic laboratory services. This partnership . . .
Posted on 1/26/17
How Bad Were Johnson & Johnson's Results?
After Johnson & Johnson (NYSE:JNJ) reported fourth quarter and full year results on Tuesday, the company's shares declined by a couple of points. I'll take a . . .
Posted on 1/26/17
Is This Johnson & Johnson's Next Billion-Dollar Blockbuster?
Johnson & Johnson (NYSE:JNJ) reported its fourth-quarter financials this week, and one of the bright spots in the quarter was ramping demand for Darzalex, the company's . . .
Posted on 1/26/17
3 Top Biotech Stocks to Buy Now
Don't fret about political uncertainties; now is a great time to buy biotech stocks. Three big biotechs, in particular, look to be solid picks. Here's why . . .
Posted on 1/26/17
Johnson & Johnson's 2017 Guidance Disappoints -- Could This Be the Issue?
IMAGE SOURCE: GETTY IMAGES.Before the opening bell on Tuesday morning, healthcare conglomerate Johnson & Johnson(NYSE:JNJ) kicked off earnings season for the sector by reporting its fourth-quarter . . .
Posted on 1/26/17
Enteris BioPharma Enters into Agreement with Nordic Bioscience's KeyBioscience
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, today announced the initiation of a clinical manufacturing services agreement . . .
Posted on 1/25/17
SOTA Medical Products and SafeOp Surgical Ink Distribution Agreement
CEDAR GROVE, N.J.--(BUSINESS WIRE)--State of the Art Medical Products, Inc. today announced that it has signed a three-year distribution agreement with SafeOp Surgical, Inc., a privately . . .
Posted on 1/25/17
Johnson & Johnson: Buy The Dip?
IntroductionJohnson & Johnson (NYSE:JNJ) has reached the iconic level reached by International Business Machines (NYSE:IBM) years ago, where the initials fully describe the company. As one . . .
Posted on 1/25/17
Johnson & Johnson Opens 2017 on a Cautious Note
Investors look to Johnson & Johnson (NYSE:JNJ) to provide a complete picture of the healthcare industry. With its pharmaceutical, medical device, and consumer products businesses, Johnson . . .
Posted on 1/25/17
How Will Johnson & Johnson Fare Under President Trump?
"Excited" -- but with a "lot of uncertainty."Those words were used by Johnson & Johnson (NYSE:JNJ) CEO Alex Gorsky in describing his take on the healthcare . . .
Posted on 1/25/17
Uh-Oh: This Could Be Johnson & Johnson's Biggest Risk in 2017
Johnson & Johnson (NYSE:JNJ) released its fourth-quarter 2016 financials and the numbers show that the launch of a Remicade biosimilar by Pfizer, Inc. (NYSE:PFE) could pose . . .
Posted on 1/24/17
Immunomedics Mails Letter to Stockholders
MORRIS PLAINS, N.J., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) commenced mailing of a letter to stockholders in connection with its upcoming 2016 Annual . . .
Posted on 1/24/17
10 Questions That Need to Be Asked Ahead of Johnson & Johnson's Q4 Report
IMAGE SOURCE: GETTY IMAGES.Though it technically never ends, earnings season is about to kick into high gear. For about a six-week stretch, a vast majority of . . .
Posted on 1/24/17
Better Buy: Exelixis, Inc. vs. Novartis
Last year Exelixis, Inc. (NASDAQ:EXEL) was one of the best-performing stocks in biotech, notching a 164% gain. With essentially one drug driving growth, though, it looks . . .
Posted on 1/24/17
Enteris BioPharma Enters Agreement with Sanofi
Enteris BioPharma, Inc., announced today the initiation of a feasibility study agreement with Sanofi to leverage Enteris' proprietary and patented oral peptide and small molecule delivery . . .
Posted on 1/24/17
Recovery Centers of America Opens Boston Center for Addiction Treatment
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--In Massachusetts, approximately 50,000 patients suffering from substance use disorder seek help by entering detox each year, yet only 3,000 beds are . . .
Philadelphia
